PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in PAD treatment

326


Michael Jaff (Newton, USA) outlines the major recent developments in best medical therapy that will impact the treatment of peripheral arterial disease (PAD) at VEITHsymposium 2018.

(Visited 199 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here